In a significant move highlighting confidence in an innovative biotechnology platform, Renaissance Group LLC has established a new, multi-million dollar position in Halozyme Therapeutics Inc. (NASDAQ: HALO), according to a recent filing with the U.S. Securities and Exchange Commission (SEC).
The filing, dated November 5, 2025, disclosed that the investment firm acquired 478,735 shares of Halozyme during the third quarter, with the transaction valued at approximately $35.11 million. This new investment represents about 1.32% of Renaissance Group’s reported $2.65 billion U.S. equity portfolio, immediately making Halozyme its 29th largest holding out of 257 stocks.
The core attraction for Halozyme lies not in traditional drug development, but in its proprietary drug delivery technology. The company’s ENHANZE® platform, based on its recombinant human hyaluronidase enzyme (rHuPH20), is a game-changer. It enables the subcutaneous (under-the-skin) delivery of biologics that traditionally require lengthy intravenous (IV) infusions, reducing administration time from hours to mere minutes.
This technology is commercialized through a scalable licensing model with major global pharmaceutical companies. Halozyme has established partnerships with industry giants such as Roche, Pfizer, and AbbVie. Its technology is integrated into several approved drugs, including Perjeta and RITUXAN HYCELA. A recent milestone was the FDA approval of Roche’s Tecentriq Hybreza™, which utilizes Halozyme’s technology to cut administration time from 30-60 minutes for IV infusion to approximately seven minutes for a subcutaneous injection.
Halozyme’s royalty-based business model has driven robust financial performance. As of November 4, 2025, the company boasted a market capitalization of $8.11 billion. For the trailing twelve months (TTM), it reported revenue of $1.24 billion and a net income of $595.49 million, reflecting a strong net income margin of 47%.
The company has demonstrated impressive long-term growth, with sales growing at an annualized rate of 38% over the past decade. While growth moderated to 22% in the last quarter, it remains robust.
From an investment perspective, Halozyme’s stock has been a notable performer. Since its IPO in 2004, its total returns have nearly doubled those of the S&P 500. Over the past year, it delivered a 16% total return, outpacing the index. Trading at around 11 times forward earnings, many analysts consider its valuation reasonable. The company is also committed to shareholder returns, having reduced its share count by an average of 3% annually over the past five years.
It has complemented organic growth with strategic acquisitions, such as the $960 million purchase of Antares in 2022 and the recent $900 million acquisition of Elektrofi.
Market observers note that Renaissance’s investment underscores a compelling aspect of Halozyme’s business model. Unlike typical biotech firms that face the high risks and capital intensity of drug development, Halozyme generates stable revenue by licensing its proven technology platform. This “pick-and-shovel” approach mitigates the traditional risks that often deter value-oriented investors, like Warren Buffett, from the biotech sector.
With the adoption of subcutaneous delivery technologies gaining significant momentum in the biopharmaceutical industry, Halozyme’s position as a key enabler for next-generation therapies makes its future growth prospects a subject of keen market interest.
